Informed Therapy for Black Women with Triple-Negative Breast Cancer: Meeting Them Where They Are and Moving Toward Better Outcomes
Premiere Date: Wednesday, June 1, 2022This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, June 1, 2023
Note: Credit Is No Longer Available
 | Sara A. Hurvitz, MD, FACP (Moderator) Professor, Division of Hematology-Oncology Department of Medicine David Geffen School of Medicine at UCLA Co-Director, Santa Monica-UCLA Outpatient Oncology Practice Director, Breast Oncology Program Division of Hematology-Oncology University of California, Los Angeles Los Angeles, CA |
 | Rita Nanda, MD Associate Professor of Medicine Director, Breast Oncology University of Chicago Chicago, IL |
 | Kristen Whitaker, MD, MS Assistant Professor, Department of Medicine (Medical Oncology) Georgetown Lombardi Comprehensive Cancer Center Washington Hospital Center Washington, DC |
Black women are disparately affected by triple-negative breast cancer (TNBC), experiencing higher mortality rates and poorer outcomes than White women, often due to screening delays leading to later-stage diagnoses. Lifting the barriers to access begins with addressing the social determinants of health and distrust of the health care system that prevent many Black women from seeking care. Outcomes improve when health care professionals (HCPs) understand these inequities and include Black women’s perspectives in treatment decisions. When HCPs integrate patient perspectives and preferences and use guideline-driven protocols, they lessen the inequities between Black and White women with TNBC. Engaging Black women throughout the process, from earlier screening to shared treatment decision-making to inclusion in clinical trials, HCPs can meet Black women where they are and move toward better outcomes.
In this CMEO Webcast, expert faculty will discuss the health inequities Black women with TNBC face, in screening, treatment, and outcomes, and how these disparities relate to the social determinants of health. In addition, they will present treatment protocols and guidelines, including the latest agents approved to treat TNBC, to help reduce these inequities. Lastly, faculty will outline how understanding the obstacles and barriers that Black women face can help inform better treatments and outcomes.
At the end of this CE activity, participants should be able to:
- Evaluate the changing landscape of treatment options for high-risk TNBC to inform therapy plans.
- Recognize the disparate impact of TNBC in Black Women.
- Engage to empower Black women regarding mammography screenings, treatment decisions, and participation in clinical trials.
Supported by an educational grant from Merck Sharpe & Dohme Corp.
Physicians, PAs, nurse practitioners, nurses, pharmacists and clinical researchers specializing in oncology
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Live activity
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Hurvitz reports the following financial relationships:
Consultant/Advisory Board (Uncompensated): 4DPharma plc; Ambrx; Amgen Inc.; Artios Pharma; Arvinas; Biotheranostics; Daiichi Sankyo, Inc.; Dantari; Eli Lilly and Company; Genentech, Inc./Roche; Immunomedics; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; NKMAX Co., Ltd.; Pieris Pharmceuticals, Inc.; Pyxis Oncology; and Seagen Inc.
Grants (Paid to UCLA): Ambrx and Samumed, LLC
National/International Principal Investigator: Daiichi Sankyo, Inc.; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation; and Seagen Inc.
Research Support (Paid to Institution): Ambrx; Amgen Inc.; AstraZeneca; Arvinas; Bayer AG; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dignitana; Eli Lilly and Company; Genentech, Inc./Roche; Gilead Sciences, Inc.; GlaxoSmithKline; Immunomedics; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Orinove Inc.; Pfizer Inc.; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.
Steering Committee: Lilly; Daiichi Sankyo, Inc./AstraZeneca; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation; and Sanofi
Dr Nanda reports the following financial relationships:
Advisory Board: AstraZeneca; BeyondSpring Inc.; Cardinal Health; Fujifilm; Immunomedics/Gilead Sciences, Inc.; Infinity. Pharmaceuticals, Inc.; iTeos Therapeutics; MacroGenics, Inc.; Merck & Co., Inc.; OBI Pharma; OncoSec Medical Incorporated; and Seagen Inc.
Research Support: Arvinas; AstraZeneca; Celgene Corporation; Corcept Therapeutics; Genentech, Inc./Roche; Immunomedics; Merck & Co., Inc.; OBI Pharma; Odonate Therapeutics, Inc.; OncoSec Medical Incorporated; Pfizer Inc.; Seattle Genetics, Inc.; and Taiho. Oncology, Inc.
Dr. Whitaker reports the following financial relationships:
Consultant: Novartis
Grants: The V Foundation for Cancer Research
Research Support: The V Foundation for Cancer Research and National Institutes of Health (NIH)
Other Financial or Material Support: Axis Medical Education and Total Health Conferencing
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
WC-048-060122-44
